Metacrine Stock

metacrine.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $134.77MM

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Metacrine, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Metacrine’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Metacrine.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Trisha Millican
Chief Financial Officer
Karl Cremer
Vice President, Clinical Operations
Michael Downes
Kathie Huynh
Hubert Chen MD
Chief Medical Officer
Richard Heyman Ph.D
Co-Founder & Chairman
Nicholas Smith Ph.D
Senior Vice President, Chemistry
Eric Bischoff
Vice President, Development and Business Operations
Ken Song MD
President, Chief Executive Officer & Board Director

Board Members

Amir Nashat Ph.D
Polaris Partners
Richard Heyman Ph.D
Carol Gallagher
New Enterprise Associates
Kristina Burow
ARCH Venture Partners
Ronald Evans Ph.D
Andrew Guggenhime
Ken Song MD
Robert Adelman MD

Frequently Asked Questions About Metacrine’s Stock

Can you buy Metacrine’s stock?
Metacrine is not publicly traded on NYSE or NASDAQ in the U.S. To buy Metacrine’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Metacrine’s stock?
Yes, you can sell stock of a private company like Metacrine. Forge can help you sell your Metacrine stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Metacrine’s stock price?
Metacrine is a privately held company and therefore does not have a public stock price. However, you may access Metacrine’s private market stock price with Forge Data.
What is Metacrine’s stock ticker symbol?
Metacrine does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Metacrine Announces Pricing of Initial Public Offering
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and...
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
Metacrine Completes $65M Series C Financing |FinSMEs
Metacrine, Inc., a San Diego, CA-based innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, completed a $65m Series C financing
Updated on: Jun 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.